LOS ANGELES, July 21, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named retired four-star General Merrill A. McPeak to its Board of Directors. General McPeak served nearly four decades in the U.S. Air Force and was USAF chief of staff from 1990 to 1994. The Genesis Biopharma Board now consists of 7 members, including 5 independent directors.
"General McPeak has been a distinguished leader throughout his life, both in the military and in business. We are delighted and honored that he has joined our board," said Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma.
General McPeak commented, "I am delighted at the prospect of joining the board of Genesis Biopharma. The rapid deployment of targeted anti-cancer technologies is the key to combating these deadly diseases, and Genesis is at the forefront of some very promising developments. I hope I can help bring these new therapeutic tools into use, and at the same time help build a great company."
A career fighter pilot, General McPeak spent two years with the Air Force's elite aerobatic team, the Thunderbirds, and flew 269 combat missions during the Vietnam conflict. Senior leadership assignments included command of the 20th Fighter Wing in NATO, the Twelfth Air Force (and concurrently, commander of US Southern Command Air Forces), and the Pacific Air Forces. He was Air Force chief of staff during a period of very active U.S. involvement overseas, including Operation Desert Storm.
Following retirement from active service, General McPeak began a second career in business. He is or has been a director of several public companies, including Tektronix, TWA and ECC International. He is currently Chairman of Ethicspoint, a provider of risk management and compliance software-as-a-service, and is a director of several public and private companies, includi
|SOURCE Genesis Biopharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved